Aprea Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aprea Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $32.32M, a 57778.45% increase year-over-year.
- Aprea Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $384.88K.
- Aprea Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $55.85K, a 99.62% decline year-over-year.
- Aprea Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $14.71M, a 201.93% increase year-over-year.
- Aprea Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $2.72M, a 81.45% decline from fiscal 2024.
- Aprea Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $14.69M, a 201.48% increase from fiscal 2023.
- Aprea Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $4.87M, a 613.33% increase from fiscal 2022.
- Aprea Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $682.97K, a 55.61% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $32.32M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $2.72M 10-K · filed 2026-03-16 | |
| 2025-06-30 | $384.88K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $55.85K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $14.69M 10-K · filed 2026-03-16 | |
| 2024-03-31 | $14.71M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $4.87M 10-K · filed 2025-03-25 | |
| 2023-03-31 | $4.87M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $682.97K 10-K · filed 2024-03-26 | |
| 2022-09-30 | $584.45K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $1.54M 10-K · filed 2024-03-26 | |
| 2019-12-31 | $100.00 10-K · filed 2022-03-15 | |
| 2019-09-30 | $100.00 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |